Qure.ai Review

Qure.ai's products are deployed within clinical imaging workflows, where they process X-rays and CT scans to flag abnormalities and support clinician decision-making. For tuberculosis, the qXR tool screens chest X-rays for signs of TB, silicosis, and pediatric TB, feeding into disease surveillance systems used by public health programs. For lung cancer, the platform tracks nodules over time to measure disease progression across a patient's care pathway, from initial detection through to case management. For stroke, a care coordination suite triages patients and connects hub and spoke hospitals in real time so clinicians can act within the critical treatment window.

The website highlights that its AI models are designed to work with a range of imaging hardware, including older X-ray machines, which it says allows healthcare facilities to use existing equipment rather than requiring new infrastructure. Qure.ai references WHO evaluations of its TB screening tools, FDA clearances for some of its imaging AI products, and real-world studies measuring clinical impact, such as a published study on stroke treatment speed. It also describes work on AI biomarkers intended for use in clinical trials, in addition to its point-of-care diagnostic tools.

Qure.ai's customers include hospitals, national tuberculosis programs, ministries of health, and pharmaceutical companies. Cited partners and clients include the NHS (Greater Glasgow and Clyde, and Nottingham University Hospitals), Medtronic, AstraZeneca, Merck's Global Health Innovation Fund, Medica Group, and Lesotho's Ministry of Health. Pricing is not published on the website and is arranged directly with healthcare providers, health systems, and government programs; the product falls in the broader category of medical imaging AI alongside vendors such as Aidoc and Viz.ai.